Diabetic Foot UlcerPhase 2/3FEENICSNCT00662831
Study Of The Effect Of Fragmin In The Treatment Of Neuroischaemic Foot Ulcers In Diabetic Patients
A Phase 2/3 study testing Fragmin/ Dalteparin Sodium in people with Diabetic Foot Ulcer, run by Pfizer at 63 sites in 17 countries.
Trial summary
The purpose of the study isto see the effect of Fragmin on the healing of diabetic foot ulcers by determining the number of subjects with ≥50% reduction in ulcer surface area including intact skin healing. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Diabetic Foot Ulcer
- What is being tested?
- Fragmin/ Dalteparin Sodium
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 276 participants
- Where
- 63 sitesin 17 countries
- Study dates
- Apr 2008to Oct 2010
- Phase
- Phase 2/3
- Are there results?
- Yes, posted in the registrySummary in the doctors' view
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Male or female subjects 18 years of age with type 1 or type 2 diabetes.
- Subjects with peripheral occlusive arterial disease (PAOD) and a neuropathy disability score (NDS) of >3
Who cannot join
- Subjects who have undergone vascular reconstruction or angioplasty less than 1 month prior to randomization. Subjects with an ulcer grading of 0 or 3 and staging of A, B or D according to the University of Texas wound classification system.
- Subjects with a known bleeding disorder or evidence of active bleeding.
Trial locations and contacts
63 sites in 17 countries.
63 sites in 17 countries
United Kingdom9 sites
Pfizer Investigational Site
Barnsley, S75 2EP
Pfizer Investigational Site
Birmingham, B9 5SS
Pfizer Investigational Site
Colchester, CO4 5JL
Pfizer Investigational Site
Coventry, CV2 2DX
Pfizer Investigational Site
Dundee, DD1 9SY
Pfizer Investigational Site
Ipswich, IP4 5PD
Pfizer Investigational Site
Manchester, M13 0JE
Pfizer Investigational Site
Manchester, M13 9WL
Pfizer Investigational Site
Peterborough, PE3 9GZ
Sweden7 sites
Pfizer Investigational Site
Karlstad, 651 85
Pfizer Investigational Site
Malmö, 205 02
Pfizer Investigational Site
Stockholm, 11883
Pfizer Investigational Site
Stockholm, 141 86
Pfizer Investigational Site
Stockholm, 17176
Pfizer Investigational Site
Stockholm, 182 88
Pfizer Investigational Site
Stockholm, 18288
Denmark6 sites
Pfizer Investigational Site
Aalborg, 9100
Pfizer Investigational Site
Aarhus C, 8000
Pfizer Investigational Site
Hvidovre, 2650
Pfizer Investigational Site
Koebenhavn NV, 2400
Pfizer Investigational Site
Odense C, 5000
Pfizer Investigational Site
Sønderborg, 6400
Russia6 sites
Pfizer Investigational Site
Moscow, 109240
Pfizer Investigational Site
Moscow, 115998
Pfizer Investigational Site
Moscow, 119034
Pfizer Investigational Site
Moscow, 123423
Pfizer Investigational Site
Moscow, 127486
Pfizer Investigational Site
Saint Petersburg, 194156
Poland5 sites
Pfizer Investigational Site
Gdansk, 80-952
Pfizer Investigational Site
Lodz, 90-153
Pfizer Investigational Site
Puławy, 24-100
Pfizer Investigational Site
Warsaw, 02-097
Pfizer Investigational Site
Wroclaw, 51-124
Greece4 sites
Pfizer Investigational Site
Athens, 106 76
Pfizer Investigational Site
Athens, 11527
Pfizer Investigational Site
Melissia/Athens, 15127
Pfizer Investigational Site
Thessaloniki, 56429
Italy4 sites
Pfizer Investigational Site
Florence, 50139
Pfizer Investigational Site
Pisa, 56124
Pfizer Investigational Site
Roma, 00133
Pfizer Investigational Site
San Giovanni Rotondo, FG, 71013
Ukraine4 sites
Pfizer Investigational Site
Kharkiv, 61002
Pfizer Investigational Site
Kyiv, 02091
Pfizer Investigational Site
Lviv, 79010
Pfizer Investigational Site
Odesa, 65009
Austria3 sites
Pfizer Investigational Site
Klagenfurt, A-9020
Pfizer Investigational Site
Vienna, A-1030
Pfizer Investigational Site
Vienna, A-1090
Czechia3 sites
Pfizer Investigational Site
Prague, 140 21
Pfizer Investigational Site
Prague, 150 06
Pfizer Investigational Site
Zlín, 760 01
Lithuania3 sites
Pfizer Investigational Site
Kaunas, 49476
Pfizer Investigational Site
Vilnius, 01102
Pfizer Investigational Site
Vilnius, 10207
Spain3 sites
Pfizer Investigational Site
Getafe, Madrid, 28905
Pfizer Investigational Site
Girona, 17007
Pfizer Investigational Site
Madrid, 28040
Canada2 sites
Pfizer Investigational Site
Montreal, Quebec, H1T 2M4
Pfizer Investigational Site
Winnipeg, Manitoba, R3A 1R9
About this study
Official title: A 6 Month, Prospective, Randomized, Double Blind, Placebo-Controlled, Parallel Group, Multiple Center Trial To Evaluate The Efficacy And Safety Of Fragmin In The Treatment Of Chronic Neuroischaemic Foot Ulcers In Diabetic Patients
The purpose of the study isto see the effect of Fragmin on the healing of diabetic foot ulcers by determining the number of subjects with ≥50% reduction in ulcer surface area including intact skin healing.
- Conditions
- Diabetic Foot Ulcer
- Being tested
- Fragmin/ Dalteparin Sodium, Placebo for Fragmin/ Dalteparin Sodium
- Keywords
- Diabetic Foot Ulcers Neuroischaemic
- Medical subject headings
- Diabetic Foot
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Fragmin/ Dalteparin SodiumDrug
Pre-filled syringes containing a single dose of 5000 IU Fragmin/ Dalteparin Sodium.
Placebo for Fragmin/ Dalteparin SodiumDrug
Pre-filled syringes containing a single dose of placebo for 5000 IU Fragmin/ Dalteparin Sodium.
| Study group | Role | What they receive |
|---|---|---|
| Active | Experimental | Active study treatment Receives: Drug: Fragmin/ Dalteparin Sodium |
| Placebo | Placebo comparator | Placebo Receives: Drug: Placebo for Fragmin/ Dalteparin Sodium |
What is being measured
The primary outcome is the main question the study is designed to answer.
Number of Participants With Greater Than or Equal to 50 Percent Reduction in Ulcer Surface Area Including Intact Skin Healing
University of Texas (UT) system assesses ulcer depth, wound infection and clinical signs of lower-extremity ischemia. UT Wound Classification (1C/2C) was based on grade (0= healed site to 3= penetrating wound to bone or joint) and stage (A= clean wounds to D= ischaemic infected wounds) of wounds. Participants were evaluated at 4 stratums: Stratum 1: Toe pressure>30 mm of mercury (mmHg) and UT grade and stage 1C. Stratum 2: Toe pressure<=30 mmHg and UT grade and stage 1C. Stratum 3: Toe pressure>30 mmHg and UT grade and stage 2C. Stratum 4: Toe pressure<=30 mmHg and UT grade and stage 2C.
Measured: Week 24 [end of treatment (EOT)] or early termination
Secondary outcomes (13)
Number of Participants With Intact Skin Healing
Intact skin healing was defined as 100 percent reduction in ulcer surface area with full epithelialisation. UT system assesses ulcer depth, wound infection and clinical signs of lower-extremity ischemia. Participants were evaluated at 4 stratums: Stratum 1: Toe pressure>30 mm of mercury (mmHg) and UT grade and stage 1C. Stratum 2: Toe pressure<=30 mmHg and UT grade and stage 1C. Stratum 3: Toe pressure>30 mmHg and UT grade and stage 2C. Stratum 4: Toe pressure<=30 mmHg and UT grade and stage 2C.
Measured: Week 24 (EOT) or early termination
Number of Participants Who Underwent Any Amputation
Any amputation included both major and minor amputations. A major amputation was defined as above the ankle and was reported as below-the-knee and above-the-knee amputations. A minor amputation was defined as below the ankle amputation.
Measured: Week 24 (EOT) or early termination
Number of Participants Who Underwent Major and Minor Amputation
A major amputation was defined as above the ankle and was reported as below-the-knee and above-the-knee amputations. A minor amputation was defined as below the ankle amputation.
Measured: Week 24 (EOT) or early termination
Number of Participants With Greater Than or Equal to 50 Percent Reduction in Ulcer Surface Area Excluding Intact Skin Healing
University of Texas (UT) system assesses ulcer depth, wound infection and clinical signs of lower-extremity ischemia. UT Wound Classification (1C/2C) was based on grade (0= healed site to 3= penetrating wound to bone or joint) and stage (A= clean wounds to D= ischaemic infected wounds) of wounds. Participants were evaluated at 4 stratums: Stratum 1: Toe pressure>30 mm of mercury (mmHg) and UT grade and stage 1C. Stratum 2: Toe pressure<=30 mmHg and UT grade and stage 1C. Stratum 3: Toe pressure>30 mmHg and UT grade and stage 2C. Stratum 4: Toe pressure<=30 mmHg and UT grade and stage 2C.
Measured: Week 24 (EOT) or early termination
Number of Participants Who Died
Measured: Week 24 (EOT) or early termination
Number of Participants With Major Cardiovascular Disease Events (MCVE)
Major cardiovascular events were defined as death due to vascular cause; non-fatal myocardial infarction (MI) excluding procedure related to MI; coronary revascularization procedures not related to MIs; hospitalization for unstable angina or non-fatal stroke.
Measured: Week 24 (EOT) or early termination
Time to Intact Skin Healing
Median time taken to achieve intact skin healing which was defined as 100 percent reduction in ulcer surface area with full epithelialisation.
Measured: Week 24 (EOT) or early termination
Median Time to First Amputation
Measured: Week 24 (EOT) or early termination
Euro Quality of Life-5 Dimensions (EQ-5D)- Utility Score
EQ-5D: participant rated questionnaire to assess health-related quality of life in terms of a single utility score. It assesses level of current health for 5 domains: mobility, self-care, usual activities, pain and discomfort, and anxiety and depression; 1 indicates better health state (no problems); 3 indicates worst health state (eg, "confined to bed"). Scoring formula developed by EuroQol Group assigns a utility value for each domain in profile. Score is transformed and results in a total score range -0.594 to 1.000; higher score indicates a better health state.
Measured: Baseline and Week 24 (EOT or early termination)
Euro Quality of Life (EQ-5D)- Visual Analog Scale (VAS)
EQ-5D: participant rated questionnaire to assess health-related quality of life in terms of a single index value. The VAS component rates current health state on a scale from 0 mm (worst imaginable health state) to 100 mm (best imaginable health state); higher scores indicate a better health state.
Measured: Baseline and Week 24 (EOT or early termination)
36-Item Short-Form Health Survey (SF-36) Score
SF-36 is a standardized survey evaluating 8 aspects of functional health and well being: physical and social functioning, physical and emotional role limitations, bodily pain, general health, vitality, mental health. The score for a section is an average of the individual question scores, which are scaled 0-100 (100=highest level of functioning).
Measured: Baseline and Week 24 (EOT or early termination)
11-point Likert Pain Scale
The 11 point Likert pain scale which used a 0 (no pain) to 10 (worst possible pain) point rating system was used to assess participant's pain score. No distinction was made between neuropathy and inflammatory (nociceptive) pain.
Measured: Baseline and Week 24 (EOT or early termination)
Transcutaneous Local Tissue Oxygenation (pO2)
Transcutaneous pO2 was assessed at the dorsum of the foot in the first intermetatarsal space using an appropriately calibrated instrument. The skin oxygen partial pressure was determined by measuring the oxygen reduction current by means of a measuring cell.
Measured: Baseline and Week 24 (EOT or early termination)
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted21 Apr 2008 (estimated)
- Study startApr 2008
- Primary completionOct 2010
- Study completionOct 2010
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Posted resultsParticipant flow, outcome measures and adverse events reported by the sponsor.
- Other trials for Diabetic Foot UlcerStudies of the same condition, open and under way.
- More trials run by PfizerThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 2/3
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind
- Who is masked
- Participant, Investigator
- Enrolment
- 276 participants (actual)
Sponsor and investigators
- Lead sponsor
- Pfizer
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
- Investigators
- Pfizer CT.gov Call Center, Study director, Pfizer
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT00662831
- Sponsor's protocol ID
- A6301083
- Acronym
- FEENICS
- Status last verified
- Nov 2018
- First submitted
- 16 Apr 2008
- Last updated
- 19 Dec 2018
- Results posted
- Yes, on ClinicalTrials.gov
- Data monitoring committee
- Yes
Study at a glance
From the registry record, last updated by the sponsor on 19 Dec 2018. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A 6 Month, Prospective, Randomized, Double Blind, Placebo-Controlled, Parallel Group, Multiple Center Trial To Evaluate The Efficacy And Safety Of Fragmin In The Treatment Of Chronic Neuroischaemic Foot Ulcers In Diabetic Patients
- ClinicalTrials.gov ID
- NCT00662831
- Acronym / sponsor ID
- FEENICS / A6301083
- Conditions
- Diabetic Foot Ulcer
- Keywords
- Diabetic Foot Ulcers Neuroischaemic
- Phase
- Phase 2/3
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 276 participants (actual)
- Lead sponsor
- PfizerIndustry (pharma, biotech, devices)
- Study start
- Apr 2008
- Primary completion
- Oct 2010 (actual)
- Study completion
- Oct 2010 (actual)
- First posted
- 21 Apr 2008 (estimated)
- Results
- Posted 13 Jan 2012
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The purpose of the study isto see the effect of Fragmin on the healing of diabetic foot ulcers by determining the number of subjects with ≥50% reduction in ulcer surface area including intact skin healing.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind (participant, investigator)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Active | Experimental | Drug: Fragmin/ Dalteparin SodiumActive study treatment |
| Placebo | Placebo comparator | Drug: Placebo for Fragmin/ Dalteparin SodiumPlacebo |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (2 listed)
- Male or female subjects 18 years of age with type 1 or type 2 diabetes.
- Subjects with peripheral occlusive arterial disease (PAOD) and a neuropathy disability score (NDS) of >3
Key exclusion criteria (2 listed)
- Subjects who have undergone vascular reconstruction or angioplasty less than 1 month prior to randomization. Subjects with an ulcer grading of 0 or 3 and staging of A, B or D according to the University of Texas wound classification system.
- Subjects with a known bleeding disorder or evidence of active bleeding.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Fragmin/ Dalteparin SodiumPre-filled syringes containing a single dose of 5000 IU Fragmin/ Dalteparin Sodium. | Drug | Active |
| Placebo for Fragmin/ Dalteparin SodiumPre-filled syringes containing a single dose of placebo for 5000 IU Fragmin/ Dalteparin Sodium. | Drug | Placebo |
Primary outcome
Number of Participants With Greater Than or Equal to 50 Percent Reduction in Ulcer Surface Area Including Intact Skin Healing
Time frame: Week 24 [end of treatment (EOT)] or early termination
University of Texas (UT) system assesses ulcer depth, wound infection and clinical signs of lower-extremity ischemia. UT Wound Classification (1C/2C) was based on grade (0= healed site to 3= penetrating wound to bone or joint) and stage (A= clean wounds to D= ischaemic infected wounds) of wounds. Participants were evaluated at 4 stratums: Stratum 1: Toe pressure>30 mm of mercury (mmHg) and UT grade and stage 1C. Stratum 2: Toe pressure<=30 mmHg and UT grade and stage 1C. Stratum 3: Toe pressure>30 mmHg and UT grade and stage 2C. Stratum 4: Toe pressure<=30 mmHg and UT grade and stage 2C.
13 secondary outcomes
Number of Participants With Intact Skin Healing
Time frame: Week 24 (EOT) or early termination
Number of Participants Who Underwent Any Amputation
Time frame: Week 24 (EOT) or early termination
Number of Participants Who Underwent Major and Minor Amputation
Time frame: Week 24 (EOT) or early termination
Number of Participants With Greater Than or Equal to 50 Percent Reduction in Ulcer Surface Area Excluding Intact Skin Healing
Time frame: Week 24 (EOT) or early termination
Number of Participants Who Died
Time frame: Week 24 (EOT) or early termination
Number of Participants With Major Cardiovascular Disease Events (MCVE)
Time frame: Week 24 (EOT) or early termination
Time to Intact Skin Healing
Time frame: Week 24 (EOT) or early termination
Median Time to First Amputation
Time frame: Week 24 (EOT) or early termination
Euro Quality of Life-5 Dimensions (EQ-5D)- Utility Score
Time frame: Baseline and Week 24 (EOT or early termination)
Euro Quality of Life (EQ-5D)- Visual Analog Scale (VAS)
Time frame: Baseline and Week 24 (EOT or early termination)
36-Item Short-Form Health Survey (SF-36) Score
Time frame: Baseline and Week 24 (EOT or early termination)
11-point Likert Pain Scale
Time frame: Baseline and Week 24 (EOT or early termination)
Transcutaneous Local Tissue Oxygenation (pO2)
Time frame: Baseline and Week 24 (EOT or early termination)
Results and safety
Loading the posted results from ClinicalTrials.gov…
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 19 Dec 2018.
- Posted resultsParticipant flow, baseline, all outcome measures and adverse events.
- To obtain contact information for a study center near you, click here.Link provided by the sponsor.
Related trials for Diabetic Foot Ulcer
Recruiting
PAW-Hydrogel for Chronic Wound Healing
Diabetic Foot Ulcer (DFU), Pressure Ulcer (PU)
Active, not recruiting
Wearable Insoles for Recurrent Diabetic Ulcer Prevention
Diabetes, Peripheral Neuropathy
Active, not recruiting
Evaluation of Personalized Nutritional Intervention on Wound Healing of Cutaneous Ulcers in Diabetics
Foot, Diabetic
Not yet recruiting
Efficacy Evaluation of Turmeric-Derived Nanoparticle Hydrogel for the Treatment of Diabetic Foot Ulcer Wounds
Diabete Mellitus
Not yet recruiting
Better Care Closer to Home: Enhancing Primary and Community Care
Diabetic Foot Disease, Recurrence
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Pfizer CT.gov Call Center study director
Pfizer
63 sites in 17 countries: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 2/3 study testing Fragmin/ Dalteparin Sodium in people with Diabetic Foot Ulcer, run by Pfizer at 63 sites in 17 countries.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 2 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 19 Dec 2018. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 63 sites in United Kingdom, Sweden, Denmark, Russia, Poland and 12 more countries. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this combined phase mean?
Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.
Phase 3 studies compare the treatment with the current standard treatment or a placebo in a large group, to confirm how well it works and watch for side effects.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
Yes. Results are posted in the registry (first posted 13 Jan 2012). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Number of Participants With Greater Than or Equal to 50 Percent Reduction in Ulcer Surface Area Including Intact Skin Healing (time frame: Week 24 [end of treatment (EOT)] or early termination). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 19 Dec 2018.